This cross-sectional retrospective study examined self-perceived changes in importance of religious beliefs (RBs) following the attacks of September 11, 2001, and assessed their associations with complicated grief (CG), posttraumatic stress disorder (PTSD), and major depressive disorder (MDD). Data were collected from 608 participants 2.5 to 3.5 years after the attacks. Whereas the majority of the participants reported no change in importance of RBs, 11% reported increased importance and 10% reported decreased importance of RBs after 9/11. Decreased, but no increased, importance of RBs was found to be associated with severity of loss and trauma (i.e., loss of a child, direct exposure to the attacks, watching the attacks unfold live on TV). In addition, decreased RBs after 9/11, as compared with no change, was significantly associated with all mental health outcomes, namely CG, PTSD, and MDD. Theoretical and clinical implications are discussed.

Mirtazapine augmentation is a good choice for the treatment of SSRI-induced sexual dysfunction, and the results are typically seen later after 4-8 weeks.

Personality properties have an effect on the onset and triggering of psoriasis. The current study aimed to examine the personality of psoriasis patients in relation to the severity of the illness. Psoriasis and healthy participants completed the Beck Depression Inventory, Beck Anxiety Inventory, Maudsley Obsessive Compulsive Inventory, Temperament and Character Inventory. Severity of psoriasis was evaluated by the PASI. MANCOVA results revealed significantly higher Novelty Seeking, Harm Avoidance, Reward Dependence and Self-Transcendence scores for psoriasis group. Severity of PASI was predicted by harm avoidance and reward dependence. Personality properties should be evaluated while planning therapeutic interventions for psoriasis patients.

This study shows that dissociative experiences reduce the response to drug therapy in patients with panic disorder.

No abstract

Nitric oxide (NO) is thought to be involved in the pathogenesis of schizophrenia as well as many neuropsychiatric disease. Asymmetric dimethylarginine (ADMA) reduces the level of NO by inhibiting nitric oxide synthase (NOS) enzyme. In this study it is aimed to be investigated ADMA in patients with first-episode schizophrenia. In this study, according to DSM-IV diagnostic criteria for schizophrenia-like psychotic disorder, 49 male first-episode schizophrenia patients-whose mean age was 23.4±3.5 year-and age and education matched 30 healthy male subjects were included for comparison. ADMA levels of the patients were measured before and after 2 months of therapy. In order to rule out the conditions that may affect the levels of ADMA, people whose physical examination and laboratory findings were within normal range were included in the study. In this study plasma ADMA levels of first-episode schizophrenia patients and control group were 3.6±1.5 µmol/L and 1.02±1.02 respectively. After 2 months of antipsychotic treatment plasma ADMA levels of the schizophrenia patients decreased compared to baseline. There was no relationship between the ADMA levels and the clinical severity of the disease. It is considered to be the role of ADMA in the etiopathogenesis of schizophrenia.

No abstract

The focus of this study was the systematic evaluation of the clinical effects of the extract of ginkgo biloba (EGb) as an adjunct to the atypical antipsychotic clozapine in the treatment of refractory schizophrenia. In a placebo-controlled study, 42 patients with chronic, treatment-resistant schizophrenia, who were maintained on optimal doses of clozapine, were administered either 120 mg/day of EGb (N=20) or placebo (N=22) for 12 weeks. Clinical evaluations with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms were completed biweekly. The use of EGb as an adjunct to clozapine was effective in decreasing negative symptoms, but not positive and overall psychopathology symptoms. EGb produced a mean 7.9+/-7.0 point reduction in the total Scale for the Assessment of Negative Symptoms score compared with a mean 1.8+/-3.5 point reduction in the placebo group (P=0.034). These preliminary data suggested that EGb was found useful for enhancing the effect of clozapine on negative symptoms in patients with treatment-resistant schizophrenia.